Verve’s Cholesterol-Lowering Treatment Shows No Safety Issues in Trial
- Posted by ISPE Boston
- On May 1, 2025
Verve Therapeutics has won FDA clearance of its Investigational New Drug (IND) application for VERVE-102 for the treatment of patients with familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). VERVE-102 is a novel, investigational in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood low-density […]
Read More